Search

Displaying results 2481 - 2490 of 8517 in total
  1. Drug

    Fludarabine

    go.drugbank.com/drugs/DB01073
    ApprovedInvestigational

    Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

  2. Drug

    Oxaliplatin

    go.drugbank.com/drugs/DB00526
    ApprovedInvestigational

    [A797] Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal … Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin.

  3. Drug

    Anthrax immune globulin human

    go.drugbank.com/drugs/DB09057
    ApprovedInvestigational

    Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and … It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue

  4. Drug

    Oxabolone cipionate

    go.drugbank.com/drugs/DB13185
    Experimental

    A synthetic anabolic-androgenic (AAS) steroid, it is a derivative of 19-nortestosterone (nandrolone). It is considered as a performance enhancing drug thus is prohibited from use in sports.

  5. Drug

    Isoniazid

    go.drugbank.com/drugs/DB00951
    ApprovedInvestigational

    Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

  6. Drug

    Reviparin

    go.drugbank.com/drugs/DB09259
    Approved

    Reviparin has a molecular weight of 3.9 kDa.[A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469]

  7. Drug

    Carglumic acid

    go.drugbank.com/drugs/DB06775
    ApprovedInvestigational

    Carglumic acid was approved by the U.S. Food and Drug Administration (FDA) on 18 March 2010.

  8. Drug

    Lipegfilgrastim

    go.drugbank.com/drugs/DB13200
    Approved

    Lipegfilgrastim, previously known as XM22, is a pegylated, recombinant granulocyte colony-stimulating factor (G-CSF) that was synthetized using a highly site-specific glycoPEGylation technology [A32665 … It is used as an alternate to [DB00019] for prophylactic use in cancer patients receiving chemotherapy and at risk for developing chemotherapy-induced neutropenia.

  9. Drug

    Penicillamine

    go.drugbank.com/drugs/DB00859
    ApprovedInvestigational

    It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties. … The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine).

  10. Drug

    Cerulenin

    go.drugbank.com/drugs/DB01034
    Experimental

    Cerulenin is an antifungal agent whose activity interferes with or otherwise acts to prevent the formation of fatty acids and sterols. In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol sy...